Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States.
Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens our metabolite measurement capabilities by offering options to cost effectively and reliably quantify the substrate of interest (acetylamantadine) in a biological sample for our SSAT1 urine-based assay using Raman spectroscopy. This technology can be used in economically and resource challenged environments on a global basis once the SSAT1 assay is approved by regulators. More positive patent news is anticipated in the near future. We remain optimistic that adding critical patents would enhance the commercial value of BioMark’s technology platform.”
